AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Eko Unveils Algorithm to Assist in the Detection of Aortic Stenosis, a Valvular Heart Disease Affecting Over 3 Million People in the U.S.

June 28, 2019

Berkeley, June 28, 2019 (GLOBE NEWSWIRE) -- Eko, a Berkeley-based digital health company applying artificial intelligence and machine learning in the fight against heart disease, unveiled an investigational Aortic Stenosis (AS) detection algorithm at the American Society of Echocardiography (ASE) 2019 Scientific Sessions aimed to assist healthcare providers in the early detection of clinically significant AS.

Developed and tested in partnership with the Northwestern Medicine Bluhm Cardiovascular Institute, the early study results showed Eko’s AI was able to accurately detect AS in a cohort of Aortic Stenosis patients with a sensitivity of 97.2% and a specificity of 86.4%. The Northwestern researchers concluded that assessment using Eko’s platform is a fast and effective method to screen for significant AS and should be validated in a primary care setting.

The algorithm represents a major step forward toward Eko’s mission to empower healthcare providers with tools to more accurately detect structural heart disease during primary care visits using the most readily accessible cardiac screening tool, the stethoscope.

Aortic Stenosis is a common structural heart disease affecting more than three million patients in the United States and is estimated to affect more than 1 in 8 patients over the age of 75 around the world. The disease is often initially identified during the physical exam when a provider hears a heart murmur using his or her stethoscope, though due to the subjectivity involved in using a stethoscope, combined with the difficult task of identifying subtle heart sounds like the AS murmur, it’s common for this to be missed in symptomatic patients, who are then sent home without follow-up.

“Eko aims to partner with providers to create the highest standard of cardiovascular care,″ said Connor Landgraf, Eko’s co-founder and CEO. “The ability to detect clinically significant AS with greater accuracy using AI-assisted cardiac screening tools can help providers ensure these patients are referred to the appropriate specialist, are monitored more closely, and receive life-extending interventions in time.”

The research was presented at ASE 2019 Scientific Sessions by Dr. Brent White, where he received the 2019 ASE Foundation Top Investigator Award. Eko will continue to partner with the Bluhm Cardiovascular Institute at Northwestern to test the AS screening algorithm and intends to eventually submit the algorithm for regulatory clearance.

For more information about Eko, its products, and research pipeline, visit https://ekohealth.com/.

About Eko Eko provides software, devices, and analysis algorithms for in-clinic heart disease screening, telemedicine, and monitoring patients at home. Its products are used by clinicians at more than 2,000 hospitals treating tens of millions of patients around the world, and its most recent product, the Eko DUO, was named a 2019 Fast Company World Changing Idea. The company has FDA and European clearance for some of its existing products and is pursuing FDA clearance for its algorithms. Eko is supported by investments from ARTIS Ventures, DigiTx Partners, Mayo Clinic, Sutter Health, and others. For more information about Eko, please visit ekohealth.com. For more information on partnership inquiries, please email: contact@ekohealth.com

Disclosures: Eko’s products are intended to be used by, or with, the prescription of a healthcare professional.

Susie Hayne Lyman Agency susie@lymanagency.com